We have previously illustrated the adequacy of the Alb-R26Met model to recapitulate several features of liver cancer patients, including the resistance to RTKi used in the clinic, the high heterogeneity of alterations, and the temporal heterogeneity of tumor onset.24 The gene discussed is ALB; the disease is liver cancer.